Q2 EPS Estimates for Haemonetics Boosted by Zacks Research

Haemonetics Corporation (NYSE:HAE) – Zacks Research boosted their Q2 2028 earnings per share estimates for Haemonetics in a report released on Tuesday, March 24th. Zacks Research analyst Team now forecasts that the medical instruments supplier will post earnings per share of $1.47 for the quarter, up from their previous estimate of $1.46. The consensus estimate for Haemonetics’ current full-year earnings is $4.55 per share.

Haemonetics (NYSE:HAE) last released its quarterly earnings results on Thursday, February 5th. The medical instruments supplier reported $1.31 earnings per share for the quarter, topping the consensus estimate of $1.27 by $0.04. Haemonetics had a return on equity of 27.32% and a net margin of 13.31%.The company had revenue of $338.97 million for the quarter, compared to analysts’ expectations of $331.90 million. During the same period in the previous year, the business posted $1.19 earnings per share. The business’s quarterly revenue was down 2.7% compared to the same quarter last year. Haemonetics has set its FY 2026 guidance at 4.900-5.000 EPS.

HAE has been the subject of several other reports. Needham & Company LLC cut shares of Haemonetics from a “buy” rating to a “hold” rating in a research report on Monday, December 15th. Robert W. Baird set a $81.00 price target on shares of Haemonetics in a report on Friday, February 6th. Citigroup reduced their price objective on shares of Haemonetics from $75.00 to $70.00 and set a “neutral” rating on the stock in a research note on Wednesday, March 11th. Wall Street Zen upgraded Haemonetics from a “hold” rating to a “buy” rating in a report on Saturday, January 10th. Finally, BTIG Research reaffirmed a “buy” rating and set a $88.00 target price on shares of Haemonetics in a research report on Friday, February 6th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $83.89.

Haemonetics Stock Down 0.7%

NYSE:HAE opened at $55.54 on Friday. The firm’s 50 day simple moving average is $62.63 and its 200 day simple moving average is $64.89. The company has a debt-to-equity ratio of 1.01, a current ratio of 1.75 and a quick ratio of 1.15. Haemonetics has a one year low of $47.31 and a one year high of $87.32. The company has a market cap of $2.58 billion, a PE ratio of 15.30, a P/E/G ratio of 1.17 and a beta of 0.28.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of HAE. Kemnay Advisory Services Inc. acquired a new stake in shares of Haemonetics during the fourth quarter worth $26,000. True Wealth Design LLC lifted its holdings in Haemonetics by 6,700.0% in the fourth quarter. True Wealth Design LLC now owns 340 shares of the medical instruments supplier’s stock valued at $27,000 after buying an additional 335 shares during the period. Leonteq Securities AG bought a new stake in Haemonetics during the fourth quarter valued at $30,000. EverSource Wealth Advisors LLC boosted its position in Haemonetics by 2,640.0% during the second quarter. EverSource Wealth Advisors LLC now owns 411 shares of the medical instruments supplier’s stock valued at $31,000 after acquiring an additional 396 shares during the last quarter. Finally, Kestra Advisory Services LLC acquired a new stake in Haemonetics during the 4th quarter worth about $34,000. Institutional investors and hedge funds own 99.67% of the company’s stock.

Haemonetics Company Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.